Aldeyra Therapeutics Inc
Chiusa
1.53 6.99
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
1.43
Massimo
1.56
Entrata | -8.9B -8.9B |
|---|---|
EPS | -0.16 |
Dipendenti | 7 |
EBITDA | -2.5M -5.5M |
Utili prossimi | 3 nov 2026 |
|---|
Capitalizzazione di Mercato | -1.2M 91M |
|---|---|
Apertura precedente | -5.46 |
Chiusura precedente | 1.53 |
Aldeyra Therapeutics Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Aldeyra Therapeutics Inc Previsione
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.